NLRP3 and autoimmune thrombocytopenic purpura: While a direct link has yet to be shown with rilzabrutinib in patients with ITP, other preclinical studies have identified a role for BTK as a direct regulator of the NLRP3 inflammasome in innate immunity [28], suggesting the potential for therapeutic effects beyond increasing platelet counts in ITP that may include ITP‐associated complications attributable to chronic inflammation, such as fatigue and thromboembolism.